Shares of Neptune Wellness Solutions Inc (NASDAQ:NEPT) (TSE:NTB) have earned an average broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. Neptune Wellness Solutions’ rating score has declined by 50% in the last 90 days as a result of a number of analysts’ ratings changes.
Brokers have set a twelve-month consensus price objective of $5.66 for the company and are forecasting that the company will post ($0.02) earnings per share for the current quarter, according to Zacks. Zacks has also given Neptune Wellness Solutions an industry rank of 159 out of 256 based on the ratings given to related companies.
A number of research firms have recently commented on NEPT. BidaskClub downgraded Neptune Wellness Solutions from a “hold” rating to a “sell” rating in a research note on Saturday, February 9th. Zacks Investment Research raised Neptune Wellness Solutions from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research note on Wednesday, March 13th. Finally, Echelon Wealth Partners reissued a “buy” rating on shares of Neptune Wellness Solutions in a research note on Wednesday, January 9th.
Neptune Wellness Solutions (NASDAQ:NEPT) (TSE:NTB) last posted its earnings results on Wednesday, February 13th. The biotechnology company reported ($0.04) earnings per share for the quarter. The firm had revenue of $4.95 million for the quarter. Neptune Wellness Solutions had a negative net margin of 60.48% and a negative return on equity of 18.85%. As a group, equities research analysts forecast that Neptune Wellness Solutions will post -0.06 EPS for the current year.
Several institutional investors have recently made changes to their positions in the company. Deutsche Bank AG raised its position in shares of Neptune Wellness Solutions by 245.9% during the fourth quarter. Deutsche Bank AG now owns 517,135 shares of the biotechnology company’s stock worth $1,313,000 after purchasing an additional 367,614 shares during the period. Two Sigma Advisers LP acquired a new stake in shares of Neptune Wellness Solutions during the fourth quarter worth $367,000. Parallel Advisors LLC raised its position in shares of Neptune Wellness Solutions by 25.0% during the fourth quarter. Parallel Advisors LLC now owns 20,000 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 4,000 shares during the period. Fisher Asset Management LLC acquired a new stake in shares of Neptune Wellness Solutions during the fourth quarter worth $51,000. Finally, Renaissance Technologies LLC raised its position in shares of Neptune Wellness Solutions by 696.0% during the third quarter. Renaissance Technologies LLC now owns 93,654 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 81,889 shares during the period. 14.53% of the stock is currently owned by institutional investors.
About Neptune Wellness Solutions
Neptune Wellness Solutions Inc, a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils.
Further Reading: Rule of 72
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neptune Wellness Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neptune Wellness Solutions and related companies with MarketBeat.com's FREE daily email newsletter.